Header Logo

Connection

Patrick Arbuthnot to Hepatitis B, Chronic

Back to Details
This is a "connection" page, showing publications Patrick Arbuthnot has written about Hepatitis B, Chronic.
Patrick Arbuthnot
Connection Strength
5,229
Hepatitis B, Chronic
  1. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Adv Drug Deliv Rev. 2021 01; 168:134-146.
    View in: PubMed
    Score: 0,663
  2. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Curr Opin HIV AIDS. 2020 05; 15(3):200-207.
    View in: PubMed
    Score: 0,659
  3. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2018 01 15; 244:311-320.
    View in: PubMed
    Score: 0,524
  4. Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 2016 12; 16(12):1517-1527.
    View in: PubMed
    Score: 0,513
  5. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016 Apr; 24(4):671-7.
    View in: PubMed
    Score: 0,494
  6. Progress and Prospects of Anti-HBV Gene Therapy Development. Int J Mol Sci. 2015 Jul 31; 16(8):17589-610.
    View in: PubMed
    Score: 0,474
  7. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
    View in: PubMed
    Score: 0,450
  8. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat. 2007 Jul; 14(7):447-59.
    View in: PubMed
    Score: 0,271
  9. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver Int. 2005 Feb; 25(1):9-15.
    View in: PubMed
    Score: 0,229
  10. Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes (Basel). 2022 10 25; 13(11).
    View in: PubMed
    Score: 0,196
  11. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virol J. 2021 12 13; 18(1):247.
    View in: PubMed
    Score: 0,184
  12. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol. 2021 Jun 21; 27(23):3182-3207.
    View in: PubMed
    Score: 0,178
  13. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
    View in: PubMed
    Score: 0,119
  14. Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector. Virol J. 2025 Feb 17; 22(1):41.
    View in: PubMed
    Score: 0,057
  15. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,046
  16. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
    View in: PubMed
    Score: 0,045
  17. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol. 2001 Apr; 82(2):77-100.
    View in: PubMed
    Score: 0,044
  18. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol. 2000 Apr; 15(4):357-68.
    View in: PubMed
    Score: 0,041
  19. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun. 2000 Feb 24; 268(3):728-33.
    View in: PubMed
    Score: 0,041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.